# CNP-201 in Subjects With Peanut Allergy

> **NCT05250856** · PHASE1 · TERMINATED · sponsor: **COUR Pharmaceutical Development Company, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** CNP-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05250856
- **Lead sponsor:** COUR Pharmaceutical Development Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-14
- **Primary completion:** 2023-12-12
- **Final completion:** 2023-12-12
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Lagging Enrollment and Administrative Reasons
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250856, "CNP-201 in Subjects With Peanut Allergy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05250856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*